Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stanford University
Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide \& Cisplatin for Stage IV Breast Cancer \& Limited Prior Treatment
Age
19–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
primary breast cancer does not express CD34+
adequate organ function
You may not be if
CNS disease
Clareo Health | CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant
